Cellosaurus logo
expasy logo

Cellosaurus MVX-1 (CVCL_C3M8)

[Text][XML][JSON]
Cell line name MVX-1
Synonyms MaxiVaX-1
Accession CVCL_C3M8
Resource Identification Initiative To cite this cell line use: MVX-1 (RRID:CVCL_C3M8)
Comments Group: Patented cell line.
Population: Caucasian.
Biotechnology: Used in clinical trial of MVX-ONCO-1 a cancer immunotherapy method using cell encapsulation technology that contains dead tumor cells from the patient itself and MVX-1 cells that produce CSF2.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2434; CSF2.
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110)
Chronic myeloid leukemia (ORDO: Orphanet_521)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0004 (K-562)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
Publications

DOI=10.1093/annonc/mdw378.12
Nicolas Mach, Remi Vernet, Marie-Claude Belkouch, Patricia Luy, Virginie Ancrenaz, Patrick Teta, Nathalie Blazek, Nicole Grandjean, Joelle Wasem, Julien Grogg, T. Perez, Denis Migliorini;
MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology.
Ann. Oncol. 27 Suppl. 6:vi359-vi378(2016)

Patent=US11013790
Nicolas Mach;
Vaccination with immuno-isolated cells producing an immunomodulator.
Patent number US11013790, 25-May-2021

Cross-references
Encyclopedic resources Wikidata; Q116049837
Entry history
Entry creation15-Dec-2022
Last entry update19-Dec-2024
Version number6